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PSY123
DiagnoSiS of Liver DiSeaSeS among inDiviDuaL With hePatic 
DYSfunction DetecteD BY annuaL heaLth checkuP BaSeD on cLaimS 
Data in JaPan
Ito C1, Nishikino R1, Onishi Y2
1Japan Medical Data Center Co.,Ltd., Tokyo, Japan, 2Creativ-Ceutical K.K., Tokyo, Japan
Objectives: Objective of this study is to evaluate the diagnosis of liver diseases 
among individuals who were detected hepatic dysfunction by the annual health 
checkup (Kenshin) in Japan. MethOds: Annual health checkup data and claims 
data based on Japan Medical Data Center (JMDC) were used to evaluate the diagno-
sis of liver disease by ICD10. Individuals who had annual health checkup in 2012 
and their associated claims data were merged by unique identifiers. Individuals 
(18≤ age≤ 64) with ALT≥ 30(IU/L) were defined as hepatic dysfunction. Confirmed 
diagnoses of liver diseases were evaluated. The time to diagnosis after the annual 
health checkup and the diagnosis with liver disease by ALT levels(IU/L) (30< ALT< 60 
and 60= < ALT) were assessed. Results: Among 57,059 individuals (ALT > 30) with-
out diagnosis of any liver disease in the preceding 12 month of the annual health 
checkup, 7500(13.1%) of individuals were visited physician office within one year 
their after annual health check-ups(30< ALT< 60:5,185 and 60= < ALT:2,315). Among 
individuals visited physician office, 4,379(58.4%) of individuals were diagnosed 
with liver diseases; 30< ALT< 60: 2,733(52.7%) and 60= < ALT: 1,646(71.1%). Fatty 
liver (21.4%) was major diagnosis followed by alcoholic hepatic disease(3.0%), 
virus hepatitis(3.1%), hepatic fibrosis or cirrhosis(0.5%) and liver cancer (0.3%). The 
detection rate of each liver disease are higher in individuals with 60= < ALT com-
pared to individuals with 30< ALT< 60. Time to diagnosis was also faster among 
individual with 60= < ALT compare to individuals with 30< ALT< 60 (log-rank test: 
p < 0.0001). cOnclusiOns: The proportion of individuals diagnosed with liver dis-
ease was relatively low considering the number of individuals with hepatic dysfunc-
tion detected by the annual checkup. Individuals with higher ALT levels were more 
likely to be diagnosed with liver disease.
PSY124
the itaLian 648/96 LiSt: aPProvaLS, reJectionS anD methoDS in aifa’S 
evaLuation ProceSS BetWeen JanuarY 2013 anD maY 2015
Prada M1, Bertozzi C1, Proietti B1, Urbinati D2
1Intexo, Roma, Italy, 2IMS Health, Milano, Italy
Objectives: Through the Italian off-label/compassionate use procedure, regulated 
by Law 648/96, the Technical Committee of AIFA (CTS) can include a given medica-
tion (among innovative drugs authorised abroad, but not in Italy, drugs which have 
not yet received an authorisation but have undergone clinical trials, and drugs to 
be used for a therapeutic indication different from the authorized one) in an official 
list, allowing it to be prescribed at the charge of the National Health System (NHS). 
This study aimed to assess AIFA’s approach, by reviewing approvals, rejections and 
methods followed by AIFA for its decisions. MethOds: Reports of CTS meetings 
from January 2013 to May 2015 were reviewed, checking number and characteristics 
of drugs under evaluation, and analyzing each single decision taken by CTS. The 
impact of 648 on pricing and reimbursement decisions was also analysed (both in 
terms of price and time) Results: Out of 103 applications, 37 (35,9%) received a 
positive evaluation, 54 (52,4%) a negative evaluation and 12 (11,7%) a conditional 
approval. The main therapeutic areas represented were oncology/onco-haematology 
with 29 requests (28,2%), followed by paediatrics with 12 requests (9,2%), non-onco-
logical haematology and cardiovascular, both with 9 requests (6,9% each), neurology 
and ophthalmology. Several rare disease compounds have been evaluated. Analysis 
indicated that the drivers for the inclusion in the 648 List were the presence of 
strong clinical data, the lack of therapeutics alternatives in the Italian market, the 
rare disease condition and the paediatric indication. cOnclusiOns: In the last 
two-and-a-half years, 49 indications have been approved, ensuring new important 
safe and efficacious therapeutic options. This analysis shows the important role of 
the Italian Law 648/96, a precious tool for patients to be treated with a drug, with 
strong clinical and safety data, waiting for the whole Italian regulatory process to 
be completed.
PSY125
market acceSS trenDS in rare DiSeaSe aPProvaLS in euroPe from 2005 
to 2014
Schultz NM1, Sarangpur S1, Toumi M2, Sherman S1
1Creativ-Ceutical, Chicago, IL, USA, 2Aix-Marseille University, Marseilles, France
Objectives: Over the past decade, the European Medicines Agency (EMA) has 
granted regulatory approval to over 75 rare disease therapies and acknowledged 
hundreds of pipeline compounds with rare disease regulatory designation. In 
Europe, market access for new technologies is predominantly dependent on regu-
latory and country-specific health technology assessments. Therefore, the purpose 
of this analysis was to examine how the impact of United Kingdom (UK) health 
policies affected the market access of rare disease technologies during 2005-
2014. MethOds: A list of approved rare disease health technologies was con-
structed utilizing publically available data from the EMA. The technologies had to 
adhere to European specific rare disease designation guidelines for study inclusion. 
Secondly, the list was cross-referenced with the National Institute of Health and 
Care Excellence (NICE) repository of appraised technologies. Information extracted 
from the NICE repository included: complete appraisal document, incremental cost-
effectiveness ratio (ICER), and final agency recommendation. Thirdly, an Excel work-
sheet was created and several descriptive techniques were used for trend analysis, 
including: calculating the proportion of NICE appraisal of EMA approvals, EMA/
NICE annual approval rate, and ICER range across NICE appraisals. Results: A 
Positive trend in rare disease technology regulatory approvals from 2005-2014 was 
observed in Europe (average increase of 1.2 approvals/year), with the highest number 
of approvals occurring in 2014 (total approvals = 15). The trend in NICE approv-
als during this period remained flat at an average of 0.2/year (5 currently under 
review in 2014), despite the number of appraisals increasing an average of 0.5/year. 
Objectives: Anaemia is a frequent complication among patients with Chronic 
Kidney Disease (CKD). This retrospective, observational study quantifies health-
care resource utilization (HCRU) and costs associated with anaemia in an Italian 
cohort of CKD-NOD patients. MethOds: Administrative data and clinical laboratory 
files of 7 Italian LHUs from 2006 and 2011 were used to identify patients with CKD 
(stage3b, 4, 5) and anaemia. Included patients had anaemia (≥ 2 haemoglobin [Hb] 
measurements 1 week–3 months apart < 13 g/dL for males, < 12 g/dL for females) 
associated with CKD-NOD stage 3b, 4, or 5. HCRU included CKD-anaemia medica-
tions, laboratory tests, haematologist/cardiologist visits, and hospitalisations for 
CKD-anaemia or cardiovascular disease (CVD). Costs were calculated using Italian 
prices and tariffs. Results: 1,654 patients were included. Overall, 542 (32.8%) of all 
1,654 patients received anaemia medications during follow-up. The prevalence of 
anaemia medication use and number of prescriptions for these medications were 
higher at higher CKD stage, although the low numbers of patients in stage 5 (from 
28.3% for stage 3b to 55.3.% for stage 5). ESAs were prescribed to 85.7% of CKD stage 
5 patients whereas CKD stage 3b patients received mostly oral iron (60.2%). Patients 
receiving any anaemia-related medications had lower per patient-per year cost 
for all studied resources compared to patients not receiving any medications. For 
anaemia-related outpatient services [treated and not treated]: stage 3b costs per 
patient year were € 61.86 and € 65.46 respectively; € 60.79 and € 73.31 for stage 4; € 63.40 
and € 81.26 for stage 5. For general visits: € 175.87 and € 194.61 for stage 3b; € 152.32 
and € 186.73 for stage 4; € 152.36 and € 342.09 for stage 5. For CV hospitalizations costs 
were € 1531.91 and € 1740.88 for stage 3b; € 1,152.27 and € 2,194,06 for stage 4; € 527.79 
and € 483.44 for stage 5. cOnclusiOns: Anaemia management may help lower both 
anaemia-related outpatient services and CV complications costs.
PSY121
heaLthcare reSource conSumPtion anD coSt of care in PatientS 
With autoSomaL Dominant PoLYcYStic DiSeaSe (aDPkD) in itaLY
Degli Esposti L1, Veronesi C1, Crovato E1, Buda S1, Santoro A2, Piccinelli R3
1CliCon S.r.l., Ravenna, Italy, 2Policlinico S Orsola-Malpighi, Bologna, Italy, 3Bergamo LHU, 
Bergamo, Italy
Objectives: To assess the consumption of healthcare resources in patients with 
polycystic kidney disease, and analyse related costs MethOds: Database analysis of 
administrative databases, containing information on beneficiaries of two Local Health 
Units, for around 2 million subjects. Data from all patients with polycystic kidney 
disease in the period January 2010 - December 2012 were analysed, the index-date 
was the date of diagnosis at hospitalisation; for patients on dialysis, index-date was 
the first day of dialysis during enrolment period Results: 608 patients with poly-
cystic kidney disease were enrolled (ICD-9 753.1), 11.2% were ADPKD patients. 1.5% 
of patients was ARPKD, in 16.3% genotype was not specified, and in the remaining 
ones the disease had not been classified.These four sub-populations were analysed, 
and the 68 ADPKD patients reported some differences from the overall population 
enrolled. Mean age in ADPKD group was 45.9 years, versus 57 of the entire sample, 
and the incidence of dialysis was 4-fold (29.4% compared to an overall 7.9%).1-year 
consumption of healthcare resources for the 20 dialysed patients with ADPKD was 
higher than in non-dialysed patients: 27.5 drug prescriptions compared to 15.2, and 
27.6 recurrences to ambulatory care services compared to 5.1, respectively.Health 
expenditure for ADPKD dialysed patients was € 36,999.30 per year, € 28,545.30 for 
ambulatory care (96% dialysis-related), € 4’695.45 for hospitalizations and € 3’758.55 
for drugs.For non-dialysed ADPKD patients, total expenditure was € 4’534.79, with € 
2,017.44 for hospitalisations; drugs cost was € 1,998.60 - 5% of which for anti-hyper-
tensives - and ambulatory care services amounted to € 518.75 cOnclusiOns: The 
reported higher incidence of dialysis - and a lower mean age - highlight the severity 
of PKD connected to the autosomal dominant type, that eventually leads to an annual 
burden for NHS of about € 37’000 for each ADPKD dialysed patients
PSY122
Patient unDerStanDing anD attituDeS aBout BioSimiLarS: an 
internationaL croSS-SectionaL SurveY
Jacobs IA1, Singh E2, Sewell KL3, AL-Sabbagh A1, Shane LG1
1Pfizer Inc, New York, NY, USA, 2Pfizer Inc., Collegeville, PA, USA, 3Pfizer Inc, Cambridge, MA, 
USA
Objectives: To understand current levels of awareness, usage, and knowledge 
of biosimilars. MethOds: Interviews (10 to 20 minutes of close-ended questions) 
were conducted online in adults categorized as: 1) Diagnosed: patients with Crohn’s 
disease, ulcerative colitis, rheumatoid arthritis, psoriasis, breast cancer, lung cancer, 
colorectal cancer, or non-Hodgkin’s lymphoma; 2) Diagnosed Advocacy: individuals 
with these diseases who participated in patient support groups; 3) Caregiver: has a 
loved one with these conditions and is involved in medical decisions; or 4) General 
Population: aged 18 to 64 years without (nor loved ones with) these conditions. 
Groups were analyzed using the column proportions test with a 95% confidence 
interval. Results: A total of 3,198 individuals responded. Awareness about biologic 
therapies, defined as the percentage of respondents reporting at least a general 
impression of biologics or that they knew the term “biologic”, was significantly 
higher in the Diagnosed, Diagnosed Advocacy, and Caregiver groups (45-78%) than 
the General Population (27%; P < 0.05). Across all groups, awareness of biosimilars 
was low with only 6% of respondents from the General Population reporting at least 
a general impression of biosimilars, although this was significantly higher among 
respondents in the Diagnosed Advocacy group (20-30%; P < 0.05). Several gaps in 
respondents’ knowledge about biosimilars were noted including safety, efficacy, and 
access to these agents. Respondents had generally positive perceptions of clinical 
trials although some barriers to participation were identified such as concerns 
about side effects, assignment to placebo rather than an active treatment, and 
time commitments. cOnclusiOns: As more biosimilars are becoming approved, 
this study reinforces that there is still an immediate need to provide education to 
all stakeholders about general biosimilar education and biosimilar clinical trials. 
These efforts will support patient choice and ensure that educated and informed 
decisions are made about the use of biosimilars.
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tables. The vast majority of included studies were carried out in Europe, being 4 of 
them in United Kingdom. Ten studies considered lifetime horizon and two studies 
five- and one-year horizon. Diabetics and non-diabetics patients were taken into 
account in almost all models. Changes in body mass index (BMI) promoted by the 
pharmacotherapy were correlated to the risk of experiencing coronary heart dis-
eases, stroke or death in ten studies. Furthermore, two models took into account 
natural BMI increasing due to population ages. Besides BMI, some models were 
sensitive to changes in total cholesterol, HDL, systolic blood pressure and gly-
cated hemoglobin for diabetics. Finally, equations derived from Framingham Heart 
Study (FHS) were the most common ones used to populate models and competing 
risks events were not discussed in most of studies. cOnclusiOns: Health-state 
transition modelling seems to be the most appropriate methodology to assess 
obesity’s pharmacotherapy. Future studies should explore other co-morbidities 
and competing risks events. Furthermore, equations used to populate models 
must be coherent to target population characteristics.
PSY129
ePiDemioLogY anD heaLthcare ServiceS utiLization for rare DiSeaSeS 
in itaLY
Polistena B1, Spandonaro F1, Zocchetti C2, Daina E3
1University of Rome Tor Vergata, Rome, Italy, 2Lombardy Region, Milano, Italy, 3Mario Negri, 
Milano, Italy
Objectives: Rare diseases (RD) are an important bench test case for healthcare 
services organization. This for both moral and ethical aspects which implies know-
ing how to cope with the needs of a vulnerable sector of population. At the same 
time RD its a challenge for healthcare service organizations, which are called to 
respond to particularly emphatic individual requirements. MethOds: The study 
has been developed on administrative database of the Regional health care system 
of Lombardia Region, containing all the services provided to resident population 
and the related costs (or tariffs recognized by the the Regional System). The analy-
sis includes all the citizen benefiting of an exemption from copayments due to 
a rare diseases condition. The RHS (regional health care system) perspective has 
been adopted. Results: The analysis covered 44,548 subjects with copayment 
exemption due to RD. The prevalence (2012) was equal to 0.46% of the resident 
population, with a significant gender difference: 0.39% for males and 0.53 % for 
females. The average annual expenditure per rare diseased patient amounts to € 
5,003.1, a value approximately comparable to the average one for patients with at 
least two chronic conditions (€ 4,500.2). In terms of gender the figure for women 
(€ 3,539.3) is significantly lower than that for males (€ 6,856.6). The total impact 
on RHS is € 222.9 M, equal to 1.21% of regional spending. Patients with ultra rare 
disease are characterized by costs (€ 6,953.6 pro capita) significantly above the aver-
age. cOnclusiOns: the research give some original insight on the prevalence and 
economic impact of RD patients in a large population. It permits to appreciate the 
potential organizational and economic impact od RD patients, especially of those 
with an ultra-rare condition, as well as financial risk for the local health care units 
due to prevalence concentration.
PSY130
comPrehenSive revieW of orPhan DrugS PoSt-amnog in germanY
Leibfried MJ, Jun K, Neuner C, Arsiwalla MY, Richardson SK
GfK Market Access, New York, NY, USA
Objectives: In Germany, orphan drugs are assessed based on their EMA orphan 
designation and expected annual budget impact. Per German law, the additional 
benefit criteria is automatically met if the product is a qualified orphan drug. 
Products with expected annual budget impact of ≤ € 50 million annually qual-
ify and therefore are only required to submit an abbreviated dossier. Products 
with expected budget impact > € 50 million must submit a full dossier and are 
assessed on ability to demonstrate added benefit. This examines how orphan 
drugs have been reviewed post-AMNOG in Germany, including their resulting price 
rebates. MethOds: GfK reviewed all EMA orphan-designated market authoriza-
tions since 2011 and cross-referenced products with the dossier submitted. GfK 
then reviewed G-BA resolutions to determine which target populations, population 
sizes, and comparators had been evaluated to determine final benefit assess-
ments. Subsequently, individual product prices were researched to determine the 
corresponding negotiated AMNOG rebates. Results: From 2011 to 2015 40 EMA 
orphan designated products received marketing authorization - only 16 of these 
products were assessed as orphan drugs in Germany. Of these, 10 were indicated 
for oncology (62.5%) and 6 (37.5%) for non-oncology indications. In their largest 
sub-populations, 8 (50%) products achieved ‘minor additional benefit’, 6 (37.5%) 
received ‘unquantifiable additional benefit,’ while only 2 (12.5%) achieved ‘con-
siderable additional benefit.’ Across 11 products, the average total rebate (AMNOG 
negotiated rebate + mandatory rebate) was 32%, however, varied highly and ranged 
between 15% and 50%. Our analysis also looked across other factors (e.g., rebate as 
it relates to benefit rating). cOnclusiOns: Due to their expected budget impact, 
most EMA orphan-designated drugs did not qualify for the abbreviated dossier. 
However, neither a full or abbreviated submission could concretely be linked to 
a higher benefit assignment; high benefit scores do not necessarily guarantee 
smaller rebates off the free price.
PSY132
the contriBution of informaL caregiver BurDen to hta in 
hematoLogicaL cancerS in france, germanY, anD the uS
Shingler SL1, Grant C1, McKendrick J2
1PRMA Consulting, Fleet Hampshire, UK, 2PRMA Consulting, Hampshire, UK
Objectives: Informal caregiver burden is not formally or routinely considered in 
health technology assessment (HTAs). However, the burden of many diseases on 
informal caregivers’ quality of life has been recognized, including hematologi-
cal cancers. This study aimed to understand the role of informal caregiver burden 
in HTA in France, Germany, and the US, using the example of multiple myeloma 
Furthermore, the highest approved ICER value of all NICE appraised rare disease 
submissions was noted at £47,200/QALY, while 7 technologies with ICERs above 
£50,000/QALY were rejected. cOnclusiOns: ICER thresholds in the UK continue 
to be barriers to access therapies for rare diseases, although recent policy revisions 
may lead to changes in access in this market.
PSY126
chaLLengeS for aSSeSSing the economic vaLue of orPhan DrugS - a 
Literature revieW of current anD aLternative aPProacheS
Cote S1, Gaudig M2, Nielsen SK3, Shields GE4, Britton JA4
1Janssen-Cilag, Bucks, UK, 2Janssen Health Economics & Market Access EMEA, Neuss, Germany, 
3BresMed, Panjim, India, 4BresMed, Sheffield, UK
Objectives: Assessing the economic value (EV) of orphan drugs (ODs) within the 
existing health technology assessment (HTA) framework is challenging. We therefore 
decided to evaluate current and alternative HTA approaches for ODs. MethOds: 
Published studies from 2000 to July 2014 focusing on methods for assessing the 
EV of ODs were identified via MEDLINE. A targeted search for recent HTA submis-
sions was also performed, covering five ODs we selected as most relevant (bosu-
tinib, brentuximab vedotin, everolimus, pomalidomide and ruxolitinib) across six 
European countries (France, Germany, Ireland, the Netherlands, Sweden and the 
UK). Results: Eleven published papers were identified. All papers concluded that 
ODs are not suited to standard economic evaluations and the current HTA frame-
work. The primary reasons were inadequate evidence of efficacy due to low patient 
numbers, lack of important outcome measures such as quality of life, no long-term 
outcomes data, and no information on the systemic impact of the disease beyond 
the health impact, i.e. financial, emotional and social. The inherent uncertainty 
regarding short- and long-term health gains combined with high acquisition costs 
leads to incremental cost-effectiveness ratios well beyond existing HTA thresh-
olds. We identified alternative methods such as including societal value, emphasis-
ing burden of illness and using variable thresholds, weighted outcome measures, 
surrogate markers and alternative statistical approaches like Bayesian methods. 
However, none of these have been implemented in existing HTAs. We confirmed 
this in our review of HTAs, which also showed inconsistency in decisions taken by 
HTA bodies. cOnclusiOns: Assessing EV of ODs remains a challenge. Despite being 
discussed in the literature, no innovative methods have been used in recent HTA 
submissions. HTA bodies, companies developing ODs, patients and society must 
engage in further discussions on how to assess value. Until then, considerable risk 
remains that access to ODs is unequal compared to non-ODs and across countries.
PSY127
orPhan anD uLtra-orPhan technoLogieS: euroPean anD auStraLian 
PaYer PercePtionS
Hogue S1, Brogan AP1, Croft E2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2RTI-Health Solutions, Manchester, UK
Objectives: To understand European Union (EU) and Australian payer perceptions 
and challenges in the evaluation of emerging health technologies with orphan and 
ultra-orphan designations. MethOds: In-depth, qualitative, one-on-one inter-
views were conducted with payer decision makers representing Australia and the 
EU-5: France, Germany, Italy, Spain, and the United Kingdom from the RTI Health 
Solutions Payer Advisory Panel. Results: Payers identify the biggest challenges as 
lack of clinical and comparative efficacy data and pressures from advocacy groups, 
patients, and prescribers to fund the ever-increasing numbers of orphan and ultra-
orphan technologies, which are often very expensive and have limited clinical evi-
dence. Understanding the disease and its burden and unmet needs was consistently 
highlighted. All payers estimated that spending for orphan and ultra-orphan tech-
nologies will increase significantly in the next 5 years, leading to concerns over 
future funding and budgets. Clawbacks in France will be common; employment 
of the rule of rescue in Australia and pricing pressures in Italy, Spain, and the UK 
are to be expected. Payers wanted to see better-defined patient populations and 
unmet needs accompanied by well-defined treatment courses (e.g., when to stop 
treatment). Benefits of new technologies will not be captured in traditional health 
economic analyses, thus increasing uncertainty. Bridging the clinical evidence with 
other robust data will be critical. The cost to the systems was highlighted as a con-
sistent concern. More emphasis on showing the value, affordability, comparative 
effectiveness, and cost offsets is critical. cOnclusiOns: Payers are seeking more 
value-based information to better inform decision making in the evaluation of new 
orphan and ultra-orphan technologies. The challenge lies with the value of the new 
technology and who is judging that value. Rising costs of orphan and ultra-orphan 
technologies will have more impact on market access in the future, with increasing 
resistance to high prices.
PSY128
DoeS a neW Pharmacoeconomic moDeL iS DemanDeD for oBeSitY’S 
PharmacotheraPY aSSeSSment?
Riveros BS1, Luchetta RC2, Radominski R2, Correr CJ2, Wu O1
1University of Glasgow, Glasgow, UK, 2Federal University of Parana, Curitiba, Brazil
Objectives: To describe and discuss existing pharmacoeconomic models assess-
ing obese or overweight patients being treated with anti-obesity drugs MethOds: 
Medline and EMBASE were searched for cost-effectiveness or cost-utility-analy-
sis reporting in full decision modelling used. It was eligible for assessment only 
studies considering Quality Adjusted-Life Years or Life-Year Gained as the final 
outcome and assessing pharmacotherapy as intervention. Data regarding popula-
tion, study’s perspective, time-horizon and methodology used were described. It 
was discussed the sensitivity of the model for obesity’s co-morbidities such as 
cardiovacular diseases and type 2 diabetes mellitus and their reliability with clini-
cal practice. In addition, it was explored the risk equations used to populate the 
model. Results: From 51 studies assessed in full, twelve of them complied with 
our inclusion criteria being that were identified twelve different models. The most 
common methodology used was health-state transition modelling followed by life-
